Global pharma giant Novartis has locked in its biggest US manufacturing push yet.

 

The company has finalized plans for a seventh new facility as part of a sweeping $23 billion investment aimed at reshaping how it develops and delivers medicines in the United States.

 

The latest addition—a new active pharmaceutical ingredient (API) facility in Morrisville, North Carolina—will produce key components for solid dosage tablets, capsules, and RNA therapeutics. Once operational, it will complete a critical missing link in Novartis’ US footprint: end-to-end manufacturing, from raw active ingredients to finished medicines, entirely on American soil.

 

The 56,200-square-foot site expands Novartis’ North Carolina presence to five facilities across three locations, reinforcing what is fast becoming one of the company’s core global hubs for advanced drug production.

 

This milestone marks the seventh facility confirmed within a year of the company’s initial US investment announcement, underscoring the speed and scale of its expansion strategy. Novartis says the network is designed not only for today’s treatments, but to support next-generation therapies in areas like oncology, neuroscience, and rare diseases.

 

“Last year we committed to adding seven new facilities in the US, and today we finalize our plans to expand our US manufacturing and R&D footprint in the US,” said Vas Narasimhan, CEO of Novartis. 

 

"By building a connected, end-to-end footprint, we are strengthening our ability to locally develop, produce, and deliver medicines at scale, enabling timely access to innovation for patients in the US.”

 

The company says it has made rapid progress since April 2025 on its goal to manufacture all key Novartis medicines for US patients within the country—particularly high-demand and time-sensitive treatments such as radioligand therapies.

 

The expansion drive has accelerated across multiple states:

 

In February 2026, Novartis broke ground on a biomedical research center in San Diego, California, expanding its US research network alongside Cambridge, Massachusetts, and strengthening work in neuroscience and oncology.

 

The same month, it announced a new radioligand therapy (RLT) manufacturing facility in Denton, Texas, extending its cancer treatment production network to five sites.

 

In January 2026, it unveiled another RLT facility in Winter Park, Florida—the first of its kind in the Southeastern US.

 

In December 2025, the company began construction on a major North Carolina manufacturing hub for tablets, capsules, biologics, and packaging across multiple therapeutic areas.

 

In November 2025, Novartis opened a California RLT facility in Carlsbad, serving patients across the Western US, Alaska, and Hawaii.

 

Meanwhile, expansions continue at existing RLT sites in Indianapolis, Indiana, and Millburn, New Jersey.

 

Taken together, the buildout is steering Novartis toward a fully integrated US manufacturing system covering small molecules, biologics, RNA-based therapies, cell and gene therapies, and radioligand treatments.

 

The company says it is on track to achieve end-to-end US production across all advanced technology platforms—a first in its history.